Vaccinex, Inc. (NASDAQ:VCNX – Get Free Report) traded down 24.6% during mid-day trading on Tuesday . The stock traded as low as $0.8296 and last traded at $0.8296. 772 shares were traded during trading, a decline of 79% from the average session volume of 3,614 shares. The stock had previously closed at $1.10.
Vaccinex Stock Performance
The stock has a market cap of $2.00 million, a P/E ratio of -0.02 and a beta of 1.10. The stock’s fifty day moving average is $1.01 and its 200 day moving average is $1.02.
Vaccinex Company Profile
Vaccinex, Inc is a clinical-stage biopharmaceutical company developing novel immunotherapies targeting oncology and neurodegenerative diseases. Headquartered in Rochester, New York, Vaccinex harnesses its proprietary human antibody platform to modulate the semaphorin 4D (SEMA4D) pathway, a mechanism implicated in tumor immune evasion and neuroinflammatory processes. Its lead asset, pepinemab (VX15/2503), is an investigational monoclonal antibody designed to bind and block SEMA4D, thereby promoting immune cell infiltration in tumors and supporting neural repair in degenerative disorders.
In oncology, Vaccinex has advanced pepinemab through Phase 2 trials in solid tumors and hematologic malignancies, exploring its potential to enhance the efficacy of established checkpoint inhibitors.
Read More
- Five stocks we like better than Vaccinex
- MDA Space Targets US Defense Market With $620M Acquisition
- Carnival’s Second Quarter: Is the Stock Still Complicated?
- Domino’s Stock Slides to 52-Week Low as Investors Digest CEO Change
- Microsoft Solves AI’s Biggest Bottleneck With Chevron Deal
Receive News & Ratings for Vaccinex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccinex and related companies with MarketBeat.com's FREE daily email newsletter.
